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Antonino Carbone, Carla Pasquarello, Alexander Scherl, Helen Robertson, Maria Teresa Sciurpi, Giovanni Alunni-Bistocchi,
Luciano Binaglia, Jennifer A. Byrne, and Brunangelo Falini
We generated a murine monoclonal
antibody (B28p) detecting an antigenic
determinant shared by the immunoglobu-
lin superfamily receptor translocation-
associated 1 (IRTA1) receptor (the im-
munogen used to raise B28p) and an
unrelated 28-kDa protein that was subse-
quently subjected to extensive character-
ization. The expression of the 28-kDa
protein in normal lymphohematopoietic
tissues was restricted to B cells and
plasma cells and clearly differed from
that expected for IRTA1 (selectively ex-
pressed by mucosa-associated lymphoid
tissue [MALT] marginal zone B cells).
Two-dimensional polyacrylamide gel elec-
trophoresis (2D-PAGE)/mass-spectrom-
etry analysis identified the 28-kDa protein
as human tumor protein D52 (TPD52),
whose expression had been previously
described only in normal and neoplastic
epithelia. Specific B28p reactivity with
TPD52 was confirmed by immunostaining/
immunoblotting of TPD52-transfected cells.
TPD52 expression pattern in normal and
neoplastic B cells was unique. In fact,
unlike other B-cell molecules (paired box
5 [PAX5], CD19, CD79a, CD20, CD22),
which are down-regulated during differ-
entiation from B cells to plasma cells,
TPD52 expression reached its maximum
levels at the plasma cell stage. In the
Thiel myeloma cell line, TPD52 bound to
annexin VI in a Ca2-dependent manner,
suggesting that these molecules may act
in concert to regulate secretory pro-
cesses in plasma cells, similarly to what
was observed in pancreatic acinar cells.
Finally, the anti-TPD52 monoclonal anti-
body served as a valuable tool for the
diagnosis of B-cell malignancies. (Blood.
2005;105:2812-2820)
© 2005 by The American Society of Hematology
Introduction
Differentiation of B cells to plasma cells, in which a crucial role is
played by the plasma cell transcription factors B-lymphocyte–
induced maturation protein 1 (Blimp1), X-box–binding protein 1
(XBP-1), and multiple myeloma oncogene-1 protein/interferon
regulatory factor 4 (MUM1/IRF4),1,2 results in down-regulation of
B-cell–associated proteins and dramatic but still poorly understood
changes in the phenotypic profile.1,2 Better understanding of these
changes is relevant to the study of normal B-cell ontogenesis as
well as of multiple myeloma and lymphoma subtypes characteristi-
cally associated with plasma cell differentiation.3,4 Proteins com-
monly used as immunohistochemical markers of plasma cell
differentiation include, in addition to intracytoplasmic immuno-
globulins, CD138/syndecan-1 (a collagen-1–binding proteoglycan
possibly involved in plasma cell homing properties),5 the p63
rough endoplasmic reticulum protein (antibody VS38c),6,7 and
MUM1/IRF4 (a transcription factor expressed by a late germinal
center B-cell subset and plasma cells).8
In the course of immunizations aimed at producing a monoclo-
nal antibody (mAb) against the intracytoplasmic portion of the
human immunoglobulin superfamily receptor translocation-
associated 1 (IRTA1) protein,9 a cell surface receptor we previously
showed to be selectively expressed by mucosa-associated lym-
phoid tissue (MALT) marginal zone B cells and monocytoid B
cells,10 we generated a murine mAb (named B28p) that detects an
antigenic determinant shared by IRTA1 and an unrelated 28-kDa
protein. In this paper, we describe the characteristics of this 28-kDa
molecule that by 2-dimensional polyacrylamide gel electrophoresis
(2D-PAGE)/mass spectrometry was identified as the tumor protein
D52 (TPD52)11 and by immunohistochemistry showed a previ-
ously unrecognized12,13 strong expression in all mature B cells,
reaching its maximum level at the plasma cell stage. Moreover, in
the Thiel myeloma cell line, TPD52 coimmunoprecipitated with
annexin VI in a Ca2-dependent manner, suggesting that these
molecules may act in concert to regulate secretory processes of
plasma cells, similarly to what was previously reported in pancre-
atic acinar cells.14 These findings are of biologic relevance and also
indicate that TPD52 can serve as a new tool for the diagnosis of
B-cell malignancies.
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Materials and methods
Generation of recombinant GST-IRTA1 protein
A cDNA fragment encoding the intracellular portion of the human IRTA1
protein was subcloned into pGEX 3X (Pharmacia Biotech, Piscataway, NJ)
bacterial expression vector, in frame to glutathione S-transferase (GST),
and confirmed by sequencing. The GST-IRTA1 fusion protein was then
expressed in BL21 competent bacteria and purified by affinity chromatogra-
phy following the manufacturer’s instructions.
Production of the B28p monoclonal antibody
BALB/c mice were injected intraperitoneally (4 times, at 10-day intervals)
with 150 g of the GST-IRTA1 fusion protein plus Freund adjuvant, as
described previously.8 The hybridoma supernatants were screened by the
alkaline phosphatase antialkaline phosphatase (APAAP) technique15 on
tonsil paraffin sections. A hybridoma (named B28p), producing an immuno-
globulin G1 (IgG1) mAb that reacted strongly with all B cells and plasma
cells and weakly with tonsil epithelium, was cloned by a limiting dilution
technique and selected for further studies.
Other antibodies
Monoclonal antibodies against the IRTA1 extracellular portion (M-
IRTA1)10 and the MUM1/IRF4 protein8 were generated in one author’s
laboratory (B.F.). The anti-CD79a mAb was kindly provided by Professor
D. Y. Mason (Oxford, United Kingdom). Other antibodies were obtained
from the following sources: mAb anti-CD138 (DBA Italia, Segrate, Milano,
Italy), mAb anti-CD20 and polyclonal anti-CD3 (DakoCytomation, Glostrup,
Denmark), mAb anti–paired box 5 (anti-PAX5; Transduction Laboratories,
San Diego, CA), polyclonal antiactin (Santa Cruz Biotechnology, Santa
Cruz, CA). An affinity-purified rabbit polyclonal antibody recognizing
human and murine TPD52 was produced in one author’s laboratory
(J.A.B.).16 A secondary tetramethylrhodamine-isothiocyanate (TRITC)–
conjugated antimouse antibody was purchased from DakoCytomation.
Purified cell populations and cell lines
B cells and T cells were purified from peripheral blood of healthy donors by
Ficoll gradient centrifugation followed by MidiMACS (Miltenyi Biotec,
Bergish Gladbach, Germany) CD19 or CD3 selection. B-cell and T-cell
purity of greater than 95% was confirmed by 2-color (CD20/CD3 or
CD20/CD3, respectively) flow cytometry. Bone marrow myeloma cells
were isolated by MidiMACS CD138 selection, and plasma cell purity of
greater than 95% was confirmed on cytospins by morphologic criteria and
MUM1/IRF4 immunolabeling.
The Thiel myeloma cell line (provided by one of the authors; K.P.,
Oxford, United Kingdom) and the HeLa epithelial and the U937 myeloid
cell lines (American Type Culture Collection [ATCC], Manassas, VA) were
cultured in RPMI containing 10% fetal bovine serum plus penicillin (100
IU/mL) and streptomycin (100 g/mL).
Cell transfection
COS cells (simian fibroblasts) were transiently transfected with pMT2–
IRTA1-hemagglutin (HA) and pMT2-HA (as negative control) expression
vectors using the diethylamino ethyl (DEAE)–dextran method. Phoenix
cells (human embryonic kidney cells) were transiently transfected with
cDNAs encoding for TPD52, TPD52L1 (previously named hD53), TPD52L2
(previously named hD54), and murine TPD52 (Tpd52) using the pTL1
expression vector and the standard calcium-phosphate method; the empty
pTL1 vector served as negative control. Cells were grown in Dulbecco
modified essential medium (DMEM) containing 10% bovine calf serum,
penicillin (100 IU/mL), and streptomycin (100 g/mL); lysed; and
analyzed by Western blotting. Cells were also cytocentrifuged or grown on
chambered slides, air-dried overnight, acetone-fixed for 10 minutes, and
immunostained with B28p.
Western blotting
Western blotting with the mAbs B28p and M-IRTA1 was performed on
transfected COS or Phoenix cells, purified normal tonsil B and T cells, a
case of follicular lymphoma, 2 multiple myeloma cases, and the Thiel and
U937 cell lines. The lysis buffer’s composition was 1.5 mM MgCl2; 50 mM
Tris-HCl, pH 8.0; 150 mM NaCl; 1% Triton X-100; 5 mM EGTA
(ethyleneglycotetraacetic acid), pH 7.5; 50 mM NaF, pH 8.0; and 10%
glycerol plus a protease inhibitor cocktail (leupeptin, aprotinin, pepstatin A,
and phenylmethylsulfonyl fluoride). Following 10% sodium dodecyl sul-
fate (SDS)–PAGE, Western blotting was performed as previously de-
scribed10 using the primary mAbs as undiluted culture supernatants in an
overnight incubation.
Coimmunoprecipitation studies
The Thiel and U937 cell lines were lysed in ice-cold lysis buffer containing
0.2% Triton X-100 and either 5 mM EGTA or 1 mM CaCl2. For
immunoprecipitation, lysates were incubated with protein G–Sepharose
beads (Amersham Biosciences, Milan, Italy), followed by the B28p mAb.
After washing, the immunoprecipitates were loaded onto 10% SDS-PAGE.
Filters were immunostained with mAbs against annexin VI (BD Transduc-
tion Laboratories, San Jose, CA; at 1:5000 dilution) and B28p (undiluted
culture supernatant) and revealed as described in “Western blotting.”
Tissue and cell samples
The B28p reactivity was assessed in paraffin sections from normal and
reactive palatine tonsils (n 20), lymph nodes (n 20), spleens (n 10),
and bone marrows (n 20). We also investigated 180 lymphoid neoplasms
representative of most Revised European American Lymphoma/World
Health Organization (REAL/WHO) categories3,4 (Table 1), 40 acute
myeloid leukemias, and 18 carcinomas (6 breast, 6 colon, and 6 lung).
Tissue specimens were fixed either in buffered formalin (overnight) or
B5 (3-4 hours) and processed routinely. Bone marrow biopsies were fixed in
B5 (2 hours) and decalcified for 5 hours in ethylenediaminetetraacetic acid
(EDTA) before processing.
Table 1. Expression of TPD52 protein in paraffin sections
of lymphomas
Type
Cases,
N  180
TPD52 expression by
tumor cells*
B-cell derived
Acute lymphoblastic leukemia 30 6/30
Chronic lymphocytic leukemia 8 7/8
Hairy cell leukemia 10 10/10
Mantle cell lymphoma 5 5/5
Marginal zone lymphoma 5 4/5
FCC lymphoma 15 15/15
DLCL-B 20 15/20
Burkitt lymphoma 2 2/2
Plasma cell tumors 20 20/20†
T-cell derived
Lymphoblastic/T-ALL 15 6/15
Anaplastic large cell lymphoma 10 0/10
Other PTCL 16 0/16
Hodgkin lymphoma
Nodular sclerosis 14 6/14‡
Mixed cellularity 9 3/9‡
NLPHD 1 1/1
The expression of TPD52 protein in paraffin sections of lymphomas was
assessed using the B28p mAb. FCC indicates follicular lymphoma; DLCL-B, diffuse
large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; and NLPHD, nodular
lymphocyte predominance Hodgkin lymphoma.
*In all positive cells reactivity was cytoplasmic.
†Multiple myeloma (n  16); solitary plasmocytoma of bone (n  4).
‡Twenty percent to 80% positive tumor cells. One mixed-cellularity case was
previously misdiagnosed as ALK-negative anaplastic large cell lymphoma (see
“Results” and “Discussion”).
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B28p reactivity was also investigated on nonfixed and nonpermeabi-
lized cell suspensions from purified B and T cells and the Thiel myeloma
cell line by flow cytometry.
Immunostaining procedures
Paraffin sections were subjected to microwaving (750 W  3 cycles of 5
minutes each) using 1 mM EDTA buffer, pH 8.0, and immunostained by the
3-stage APAAP technique15 (when using mAb) or the 4-stage APAAP
technique8 (when using polyclonal antibodies). Following substrate devel-
opment, slides were counterstained in hematoxylin (5 minutes) and
mounted in Kaiser glycerol gelatin.
Double staining for B28p/MUM1-IRF4, B28p/PAX5, B28p/CD68, and
B28p/CD3 was performed using a sequential immunoperoxidase/APAAP
technique, as previously described.17 Slides were mounted in Kaiser gelatin
without counterstain.
Images were captured from stained slides using an Olympus BX61
microscope equipped with 20/0.7, 40/0.85, and 100/1.3 objective
lenses and an Olympus Camedia C-3030–zoom camera (Olympus, Tokyo,
Japan). Following acquisition with DP-Soft version 3.2 software (Olym-
pus), images were further processed with Adobe Photoshop version 4.01
(Adobe, San Jose, CA).
Flow cytometry analysis on cell suspensions was performed using an
indirect immunofluorescence procedure (the mAb B28p followed by a
TRITC-conjugated antimouse antibody).
Two-dimensional gel electrophoresis and mass spectrometry
Two-dimensional PAGE. Cells from a B28p-reactive follicular lymphoma
patient and from the B28p-unreactive U937 cells (as negative control) were
lysed in 8 M urea, 4% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-
1-propane-sulfonic acid), 40 mM Tris-hydroxymethyl-aminomethane, and
65 mM dithiothreitol (DTT).
Protein isoelectrofocusing was carried out for 85 000 volts per hour
(Vh) on immobilized linear pH gradient strips, pH 4 to 7 (Bio-Rad,
Hercules, CA). Strips were incubated for 10 minutes with 6 mL equilibra-
tion buffer (0.375 M Tris-HCl, pH 8.8; 6 M urea; 20% glycerol; 2% SDS)
containing 130 mM DTT and 10 minutes with 6 mL equilibration buffer
containing 135 mM iodoacetamide. The second dimension was run on 12%
acrylamide/piperazine-diacrylamide gel, according to Hochstrasser et al.18
Western blotting. Proteins were blotted onto Immobilon-NC membranes
(Millipore, Bedford, MA), stained with Bio-Safe Coomassie (Bio-Rad), and
scanned using an Agfa Duoscan T 1200 scanner (AGFA, Milan, Italy). Western
blotting was then performed as previously described,10 and developed films were
scanned as described in “Western blotting.” Immunoreactive spots were identi-
fied in Coomassie-stained blots by matching with Western blot images using the
Bio-Rad PDQuest software (Bio-Rad Laboratories, Milano, Italy). Two reactive
spots (S1 and S2) present in the follicular lymphoma sample but not in the U937
sample were excised from Coomassie blue–stained gels and in-gel trypsin
digested according to Moritz et al.19
Protein identification by tandem mass-spectrometry (MS/MS). Pep-
tides were eluted from gel fragments using 20 L of 0.1% trifluoroacetic
acid (TFA), and 5 L of peptide-containing solution was injected on a
home-made C18 reverse-phase column of 75m inner diameter (YMS-ODS-
AQ200; Michrom Bioresource, Auburn, CA). Peptides were eluted with an
acetonitrile (AcN) gradient in the presence of 0.1% formic acid using
SunFlow pumps (SunChrom, Friderichsdorf, Germany) and a flow splitter
to decrease the flow rate from 200 to 0.4 L/minute. Peptides were
analyzed with a quadrupole time-of-flight (Q-TOF) mass spectrometer
(Micromass, Wythenshawe, United Kingdom), applying a 2700 V potential
on the nanoelectrospray capillary (New Objective, Woburn, MA) and using
argon as the collision gas. MS/MS spectra were acquired by automatic
switching between MS and MS/MS mode. Acquired MS/MS data were
converted into a compatible format (.DTA files) by ProteinLynx software
(Micromass) and analyzed using v1.8 of the Mascot search engine20 against
Swiss-Prot,21 TrEMBL,22 NCBInr,23 and EST24 databases.
Protein identification by peptide mass fingerprinting (PMF). MS
measurements were conducted with a matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometer, Voyager super
STR (PerSeptive Biosystems, Framingham, MA) equipped with a 337-nm
nitrogen laser. Spectra were obtained by summation of 150 consecutive
laser shots. Peak masses were extracted from the spectra and used for
protein identification with Mascot20 v1.8 and the SmartIdent peptide mass
fingerprint tool25 against Swiss-Prot21 and TrEMBL22 databases.
Results
The protein recognized by B28p is expressed in mature B cells
with the highest levels in plasma cells
In palatine tonsils, in addition to the epithelium (weakly positive),
the antibody labeled the cytoplasm of all peripheral B-cell subsets
(mantle, germinal center, intraepithelial/subepithelial, and interfol-
licular B cells), the most intense positivity being observed in
plasma cells (Figure 1A). Cytoplasmic localization of the protein
recognized by B28p was also supported by the negative immuno-
staining in nonfixed/nonpermeabilized purified B cells and the
Thiel myeloma cell line at flow cytometry (not shown).
The B-cell nature of the B28p cells was confirmed by the
finding that all of them coexpressed the B-cell–specific nuclear
transcription factor PAX5 (with the exception of those clearly
morphologically recognizable as plasma cells and therefore ex-
pected to be PAX5 negative). Conversely, B28p cells were
negative for CD3 and the macrophage marker CD68 (not shown).
Notably, the staining pattern of B28p clearly differed from that
expected for the IRTA1 protein, whose expression in tonsil is
restricted to a B-cell subset located within and immediately
beneath the tonsil epithelium10 (Figure 1B).
That plasma cells were, among B cells, those containing the
highest amount of the B28p-reactive protein was particularly
evident at increasingly higher dilution of the B28p mAb, when its
reactivity with B cells markedly decreased or disappeared while
Figure 1. The protein recognized by B28p is expressed in mature B cells and
plasma cells. (A) In normal tonsil, B28p reacts with B cells and, more strongly, with
plasma cells (arrow); notice the weak positivity of tonsil epithelium (E). (B) The
expression pattern of IRTA1 in normal tonsil (as revealed by the M-IRTA1 mAb)
clearly differs from that of TPD52, labeling being restricted to a subset of B cells
located within and beneath the tonsil epithelium (E). GC indicates germinal center.
(C) The expression pattern of TPD52 in a reactive lymph node is similar to that
observed in the tonsil; the arrow points to an aggregate of strongly positive plasma
cells. (D) In a reactive bone marrow, TPD52 is strongly expressed in plasma cells
(arrow) and B cells (arrowhead), while hematopoietic precursors are negative. The
double arrow points to a TPD52-negative megakaryocyte. T indicates a bone
trabecula. The APAAP technique was used with hematoxylin counterstain. Original
magnifications, 200 (A-C) and 1000 (D).
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that with plasma cells remained strong (not shown). In serial tonsil
sections, the number of B28p and CD138 plasma cells was
comparable (not shown), although the subcellular labeling pattern
of B28p (cytoplasmic) differed from that of the CD138 protein
(restricted to the cell surface). As expected, plasma cells coex-
pressed B28p and MUM1/IRF4 (not shown). Reactivity with
mature B cells and, most abundantly, plasma cells was also
observed in reactive lymph nodes (Figure 1C), spleens (not
shown), and bone marrows (Figure 1D), where erythroid and
myeloid cells as well as megakaryocytes were B28p negative.
Outside the lymphohematopoietic system, B28p reacted with
glandular epithelia from different organs, including stomach,
pancreas, and colon (not shown), that were in turn negative for
IRTA1. The staining was usually weaker than that observed in B
cells and plasma cells.
These findings provide evidence that B28p reacts with a protein
expressed in mature B cells (with the highest level in plasma cells),
an expression pattern that clearly differs from that of IRTA1.
The B28p mAb recognizes an epitope shared by IRTA1 and an
unrelated 28-kDa protein
The B28p mAb identified a strong band of 70 to 75 kDa in Western
blots of COS cells transfected with a vector encoding for the
full-length IRTA1 protein (not shown).
Apart from this cross-reactivity with IRTA1, B28p mAb
detected a band of about 28 kDa in lysates from a follicular
lymphoma (Figure 2A, lane 2) lacking IRTA1 protein both at
Western blotting and immunohistochemistry (not shown). The
B28p mAb also identified a band of the same molecular weight
(about 28 kDa) in lysates from normal B cells purified from the
peripheral blood (Figure 2A, lane 3), from 2 multiple myeloma
cases (Figure 2A, lanes 5-6), from the Thiel myeloma cell line
(Figure 2A, lane 7), and from the epithelial HeLa cell line
(Figure 2A, lane 8). In contrast, the 28-kDa band was undetect-
able in the U937 myeloid cell line and barely detectable in
normal T cells purified from the peripheral blood (Figure 2A,
lanes 1 and 4, respectively), the latter finding being likely
accounted for by the residual B cells contaminating the greater
than 95% pure T-cell sample.
These findings demonstrate that the B28p mAb reacts with an
epitope shared by IRTA1 (whose cytoplasmic portion represented
the immunogen used to generate B28p) and an unrelated protein of
about 28 kDa associated to B cells and plasma cells, thus
confirming the immunohistochemical results.
Two-dimensional PAGE and mass spectrometry identifies the
28-kDa protein as tumor protein D52 (TPD52)
To further characterize the nature of the 28-kDa protein, we
performed mass spectrometry analysis on 2 closely located protein
spots (S1 and S2) that were detected by B28p in 2D gels/Western
blots from the B28p-reactive follicular lymphoma (Figure 3A-B)
but not from the U937 myeloid cell line (not shown). The S1 and S2
spots had an isoelectric point of pH 5.2 and pH 5.1, respectively,
and a molecular weight of 24 kDa and 25 kDa, respectively (Figure
3A-B). The minor differences in estimation of the molecular weight
of the protein in 1D-Western blot (1D-WB; 28 kDa) compared with
the 2D-WB (24-25 kDa) are likely due to the different molecular
weight standards and different electrophoresis conditions used in
these experiments.
Both tandem mass spectrometry analysis on protein spot S1 (not
shown) and peptide mass fingerprinting on protein spot S2 (Figure
3C) identified the respective spot as tumor protein D52 (Swiss-Prot
accession no. P55327).
Independent evidence that the B28p mAb recognizes TPD52
was provided by its selective reactivity with TPD52-transfected
(Figure 3D) but not TPD52L2-transfected (Figure 3E), TPD52L1-
transfected, or empty vector–transfected Phoenix cells (not shown).
The reactivity was specific for the human TPD52, since Phoenix
cells transfected with murine Tpd52 were unreactive (not shown).
The specificity of B28p for human TPD52 was also confirmed by
Western blotting that showed the expected 28-kDa band only in
lysates from TPD52-transfected but not from TPD52L1-, TPD52L2-,
or murine Tpd52–transfected Phoenix cells (Figure 2B). The same
band of 28 kDa was selectively detected in TPD52-transfected cells
by a specific anti-TPD52 rabbit polyclonal antibody16 (Figure 2C)
serving as positive control.
To further confirm that the immunoreactivity of B28p with B
cells/plasma cells in tissues was due to the expression of TPD52
protein, we also stained tonsil and marrow paraffin sections with
the anti-TPD52 rabbit polyclonal antibody.16 The staining pattern
was identical to that observed with the B28p mAb, although the
background labeling was higher (not shown). This confirms also in
lymphoid tissues the overlapping reactivities toward TPD52 of the
B28p mAb and the anti-TPD52 polyclonal antibody.
These findings demonstrate that (i) the B-cell–associated 28-
kDa protein recognized by the B28p mAb is human TPD52; and (ii)
B28p recognizes TPD52 both at Western blotting and
immunocytochemistry.
Figure 2. Western blotting of various primary samples and cell lines. (A) The
B28p mAb recognizes a 28-kDa protein expressed in B cells and plasma cells. B28p
identifies a band of approximately 28 kDa (arrow) in a Western blot of lysates from the
NHL-FCC patient sample (lane 2), peripheral blood (PB) purified B cells (lane 3), 2
multiple myeloma (MM) patients (lanes 5 and 6), the Thiel myeloma cell line (lane 7),
and the HeLa cell line (lane 8). The 28-kDa band was undetectable in the U937 cell
line (lane 1) and barely detectable in normal T cells purified from peripheral blood
(lane 4). Similar amounts of total protein lysates were loaded in each lane (see
antiactin Western blot, bottom). None of the samples showed IRTA1 expression at
immunohistochemical and Western blot analyses using the M-IRTA1 mAb (not
shown). (B-C) B28p mAb and an anti-TPD52 polyclonal antibody recognize the same
band of about 28 kDa in TPD52-transfected Phoenix cells. A band (arrow) of the
expected molecular weight of TPD52 (about 28 kDa) is selectively detected by the
B28 mAb (A) in cells transfected with human TPD52 (hTPD52) but not in cells
transfected with murine TPD52 (mTPD52) or with the empty vector. A rabbit
polyclonal antibody (here abbreviated as TPD52 pAb), known to recognize both
hTPD52 and mTPD52, detects (C) the same band of about 28 kDa (arrow) in cells
transfected with hTPD52 or with mTPD52 but not in cells transfected with the empty
vector. An antiactin Western blot is shown as loading control in the bottom part of the
2 panels.
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Ca2-dependent binding of TPD52 to annexin VI in the Thiel
myeloma cell line
Previous findings, showing that in rat pancreatic acinar cells
CRHSP28 (the rat orthologue of human TPD52) binds annexin VI
in a Ca2-dependent manner and that this molecular complex plays
a role in digestive enzyme secretion,14 prompted us to expand these
studies to plasma cells. A rationale for proceeding in this direction
also emerged from our recent finding that normal and neoplastic
plasma cells express annexin VI protein both at Western blotting
and immunohistochemistry (E.T. and B.F., unpublished results,
August 2003).
To determine whether TPD52 associates to annexin VI in
plasma cells, lysates of the Thiel human myeloma cell line (treated
either with 5 mM EGTA or 1 mM CaCl2) were immunoprecipitated
with B28p (anti-TPD52) and Western blotted with an anti–annexin
VI mAb (Figure 4). Interestingly, a TPD52–annexin VI complex
was barely detectable when lysates were prepared in the absence of
Ca2 (Figure 4 lane 5), whereas inclusion of Ca2 in the lysis buffer
caused the 2 proteins to strongly coimmunoprecipitate (Figure 4
lane 6). This Ca2-dependent association of annexin VI with
TPD52 was not due to unspecific binding of annexin VI to protein
G–Sepharose beads (Figure 4 lanes 7-8) or to the B28p mAb used
in the immunoprecipitation, because, either with or without Ca2,
no annexin VI was immunoprecipitated by B28p from lysates of
the annexin VI–positive/TPD52-negative U937 myeloid cell line
(not shown).
TPD52 expression in hematologic malignancies
The immunostaining results in 180 lymphoid neoplasms are
summarized in Table 1. TPD52 was mostly absent in tumors
derived from early precursor B cells with weak positivity being
observed in only 20% of acute lymphoblastic leukemias. In
contrast, lymphomas derived from peripheral B cells showed
consistent TPD52 expression (Figure 5A,C,E). About 25% of
diffuse large B-cell lymphomas were TPD52 negative. Some
Figure 3. 2D-PAGE and mass spectrometry identify the
28-kDa protein as TPD52. (A-B) Spots S1 and S2 (corre-
sponding to the 28-kDa band in 1D-Western blots in Figure 1)
are shown in a silver-stained 2D gel of B28p-positive lym-
phoma cells (A) and in the corresponding 2D-Western blot
probed with the B28 mAb (B). Spot S3, which represented an
unspecific reaction also detected in the negative control
(U937 cell line; not shown), was not subjected to mass
spectrometry analysis. (C) Peptide spectra. Protein S2 was
isolated from a Coomassie-stained 2D gel and digested with
trypsin. The mass of the resulting fragments was assessed by
MALDI-TOF spectrometry. Peptide masses corresponding to
TPD52 in S2 are denoted with asterisks: 1222.644 Da, 1454
Da, 1657 Da, and 2099 Da. (D-E) B28p strongly stains
Phoenix cells transfected with a construct encoding human
TPD52 (D). In contrast, no reactivity is seen toward cells
transfected with any of the constructs encoding TPD52L2 (E)
or TPD52L1, murine Tpd52, and the empty vector (not
shown). The APAAP technique was used with hematoxylin
counterstain. Original magnification, 1000.
Figure 4. Ca2-dependent coimmunoprecipitation of annexin VI with TPD52 in
the Thiel myeloma cell line. Following immunoprecipitation (IP) with mAb B28p and
protein G–Sepharose beads (Prt-G), proteins were analyzed by immunoblotting with
murine mAbs against TPD52 (B28p, bottom panel) and annexin VI (top panel; bands
in lanes 3-6 indicated by the arrowhead correspond to the heavy chains of the murine
mAb B28p, detected by the secondary antimouse antibody). Coimmunoprecipitation
of annexin VI (arrow in top panel) with TPD52 (arrow in bottom panel) was dependent
on the presence of Ca2 in the lysate (compare lanes 5 and 6).
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diffuse large B-cell lymphomas with plasma cell differentiation
showed TPD52 expression in the absence of CD20 (Figure 5C,E).
The strongest TPD52 expression was seen in plasma cell tumors
(Figure 5B,D,F).
In about 40% of classical Hodgkin lymphoma samples (espe-
cially those fixed in B5), a variable percentage of tumor cells
(ranging from 20% to 80%) showed weak to moderate cytoplasmic
expression of TPD52 (Figure 6A) in the absence of the B-cell
molecules CD20 and CD79a. Notably, in one case received in
consultation as anaplastic lymphoma kinase (ALK)–negative ana-
plastic large-cell lymphoma with null phenotype, the diagnosis was
changed into that of tumor cell–rich Hodgkin lymphoma, accord-
ing to the expression of PAX5 and TPD52 (Figure 6B-D).
No TPD52 expression was observed in peripheral T-cell lympho-
mas (Table 1). In contrast, weak TPD52 expression was detected in
about 40% of T-lymphoblastic lymphomas/leukemias (Table 1), the
percentage of positive neoplastic cells ranging from 20% to 100%.
Since a similar fraction of precursor T-cell malignancies is known
to aberrantly express CD79a,26,27 we investigated the 6 T-
lymphoblastic lymphomas/T-acute lymphoblastic leukemias (T-
ALLs) that were TPD52 and/or CD79a positive and found the
following expression patterns: TPD52/CD79a (2 cases), TPD52/
CD79a (2 cases), TPD52/CD79a (2 cases). This finding may
reflect some yet unknown function of these B-cell proteins in early
neoplastic T cells.
All 40 acute myeloid leukemias were TPD52 negative (not
shown). As expected,11 about 50% of carcinomas of breast, colon,
and lung expressed TPD52 (not shown).
The expression pattern of TPD52 differs from that of other
B-cell–associated molecules
Based on immunostaining results on normal and neoplastic
lymphohematopoietic tissues, it is clear that TPD52 up-
regulation in plasma cells makes the expression pattern of this
protein markedly different from that of other known B-cell–
associated proteins (eg, PAX5, CD79a, CD19, CD22, CD20;
Figure 7 and “Discussion”), which are all down-regulated at
variable extents upon plasma cell differentiation, or from that of
other plasma cell–associated proteins (eg, CD138, MUM1/
IRF4), which are expressed almost exclusively in plasma cells
(Figure 7 and “Discussion”).
Figure 5. TPD52 expression in lymphomas and myeloma. Strong cytoplasmic
expression of TPD52 in a case of hairy cell leukemia (A; paraffin section from bone
marrow trephine; original magnification,  200). T indicates a bone trabecula.
Plasmoblastic lymphoma in an HIV-infected patient (paraffin sections): tumor cells
express TPD52 (C; original magnification,  400) but are CD20 (E; original
magnification,  400); E indicates oral epithelium. The APAAP technique was used
with hematoxylin counterstain. (B,D,F) Tumor cells in a case of undifferentiated
myeloma (B; hematoxylin-eosin; original magnification,  1000). The myeloma cells
strongly express CD138 on the cell surface (D; APAAP technique; hematoxylin
counterstain; original magnification, 1000) and TPD52 in the cytoplasm (F; APAAP
technique; hematoxylin counterstain; original magnification,  1000); the arrow
points to a TPD52-positive multinucleated myeloma cell. All panels represent paraffin
sections from B5-fixed/EDTA decalcified bone marrow trephines.
Figure 6. TPD52 expression in Hodgkin lymphoma. (A) Mixed cellularity
Hodgkin lymphoma. Mononuclear variants show strong (arrow) and moderate
(arrowhead) TPD52 positivity (original magnification  800). (B-D) Tumor cell–
rich Hodgkin lymphoma (original magnification  400). A nodule of tumor cells (*)
that are CD30 (not shown) and CD79a (B) displays nuclear staining for PAX5
(C) and cytoplasmic labeling for TPD52 (D). The rim of residual normal B cells at
the periphery of the nodule served as positive control. Lymph node paraffin
sections. The APAAP technique was used with hematoxylin counterstain.
Figure 7. Expression of TPD52 during normal B-cell ontogenesis. Differences
in TPD52 expression compared with other B-cell/plasma cell–associated proteins
are highlighted by the corresponding bars. It is not yet determined at which
stage of normal early B-cell differentiation expression of the TPD52 first occurs
(dotted area).
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Discussion
The TPD52 gene was initially identified as being overexpressed in
human breast, lung, and prostate carcinomas16,28,29 and it is
currently recognized as a candidate target gene at chromosome
8q21,16,28,29 a region gained in many types of cancer. The encoded
TPD52 protein is a member of a highly conserved family30
(comprising TPD52, TPD52L1,30 and TPD52L231,32) of small
hydrophilic polypeptides of approximately 200 residues that share
about 50% sequence identity but bear little similarity to proteins of
known function in any species.32 These proteins share in common a
conserved coiled-coil motif that supports homomeric and hetero-
meric interactions among family members.33
The finding that all members of the TPD52 family may interact
in a heteromeric fashion with MAL2,13 a new member of the MAL
proteolipid family that is required for transcytosis in HepG2 cells,34
implies a potential involvement of TPD52-like proteins in vesicle
transport. Indeed, TPD52L1 has been shown to localize in an
endosomal compartment in PC12 cells and to stabilize the associa-
tion of synaptobrevin 2 and syntaxin 1 complexes in vitro,
implicating TPD52L1 in the promotion of soluble N-ethylmale-
imide–sensitive fusion protein (NSF) attachment protein receptor
(SNARE) complex formation and, thus, in the facilitation of
membrane fusion events.35 Moreover, an alternatively spliced
isoform of TPD52L1 has been described to specifically interact
with 14-3-3 proteins,36 which have been implicated in membrane
trafficking–related processes, including exocytosis and cytoskel-
eton dynamics.37,38
In this paper, we provide novel data about TPD52 protein
expression in normal and neoplastic human tissues as revealed by a
newly raised mAb (B28p), which 2D-PAGE/mass spectrometry
analysis found to recognize TPD52 (in addition to IRTA1, the
immunogen used in the generation of this antibody). In fact, using
Northern blotting and in situ hybridization, TPD52 transcripts were
originally found to be expressed at high levels in tumor cell lines
and in primary biopsies from breast, prostate, pancreas, kidney,
colon, and cervical carcinomas,11,12 as well as in many normal adult
and fetal tissues such as kidney, prostate, small intestine, and
pancreas.12 In contrast, only low levels of transcripts were detected
in normal lymphohematopoietic tissues (spleen, thymus, peripheral
mononuclear cells) and germ cell tissues (testis and ovary).12 The
present study demonstrates for the first time that normal and
neoplastic B cells and particularly plasma cells represent the
human cell populations that express the TPD52 protein most
consistently and at high levels. This unrecognized finding in
previous studies is likely due to the lower sensitivity of the methods
employed (Northern blotting) and/or to the possible lack of strict
correspondence between TPD52 mRNA and protein levels and/or
to the fact that B-cell/plasma cell–rich tissues (lymph nodes and
tonsil) were not analyzed.11,12 Whether expression in normal
lymphohematopoietic tissues also applies to other members of the
TPD52 family is currently unknown. Interestingly, TPD52L2
mRNA emerged as being associated to the mixed lineage leukemia
(MLL) subtype of B-cell acute lymphoblastic leukemias from a
gene expression profiling study.39 Moreover, from a gene expres-
sion analysis of normal B-cell populations and B-cell lymphomas40
it clearly emerged that TPD52 and TPD52L2 are expressed in all
stages of mature B cells (naive, germinal center, and memory) and
in all categories of B-cell lymphomas with the exception of some
diffuse large B-cell lymphomas (Riccardo Dalla Favera, Institute
for Cancer Genetics, New York, NY; personal written communica-
tion, February 2003).
In spite of its cross-reactivity with the cytoplasmic portion of
IRTA1, B28p can be regarded in practical terms as a specific
anti-TPD52 mAb suitable for immunohistochemical work, since
IRTA1 normal and neoplastic B cells are part of the TPD52-
positive B-cell populations. This is also supported by the finding
that in normal lymphoid tissues the polyclonal antibody against
TPD52 (not cross-reacting with IRTA1) produces the same
immunohistologic pattern as B28p. However, it may be advis-
able to compare IRTA1 and TPD52 stainings in order to
ascertain whether any given B-cell population expresses one or
both proteins.
The B28p mAb identifies TPD52 as a new B-cell–associated protein
whose subcellular location and expression pattern during B-cell develop-
ment clearly differs from that of previously characterized B-cell antigens
(eg, PAX5, CD79a, CD19, CD20, and CD22) or plasma cell antigens
(eg, MUM1/IRF4, CD138; Figure 7).
Selective expression of TPD52 in mature B cells and plasma
cells suggests that this protein may play an important role during
B-cell maturation. Because of the unrecognized expression of
TPD52 in lymphoid B cells, previous studies on TPD52 function
have been confined to epithelial cells. Rabbit (CSPP28) and rat
(CRHSP28) TPD52 orthologues were shown to be phosphory-
lated in response to cholinergic stimulation of gastric parietal
cells41 and to cholecystekinin stimulation of pancreatic acinar
cells,42-44 respectively. These studies concluded that CSPP28/
CRHSP28 may represent an intermediate within calcium-
sensitive signaling pathways in a variety of tissues. Indeed,
CRHSP28 has been recently shown to be serine phosphorylated
upon increasing Ca2 levels in epithelial cells.45 Finally, it has
been reported that in rat pancreatic acinar cells, CRHSP28 can
bind annexin VI in a calcium-dependent way and that this
molecular complex plays an important role in acinar cell
membrane trafficking events that are essential for digestive
enzyme secretion.14 Our finding—that in the Thiel human
myeloma cell line, TPD52 associates to annexin VI in a
Ca2-dependent manner—raises the intriguing possibility that
these molecules may act in concert to regulate secretory
processes also in plasma cells. When considering that TPD52
reaches the maximum expression level in plasma cells, its
involvement in processes related to immunoglobulin secretion
would be an appealing hypothesis. Further studies are warranted
to clarify this issue.
Because of its reactivity pattern that is different from that of
other B-cell molecules and the preservation of its target epitope in
routine paraffin sections, TPD52 represents a new tool for the
diagnosis of lymphomas associated with plasma cell differentia-
tion, including transplantation-associated lymphomas, plasmablas-
tic lymphomas of the oral cavity,46 or pleural-effusion lymphomas
(PELs).3,4 Such tumors are in fact characterized by minimal or
absent expression of B-cell lymphoma 6 (BCL6) and CD2046 and
weak to moderate positivity for CD79a.
Another interesting area of application is Hodgkin lymphoma.
The finding of weak to moderate TPD52 expression in a variable
proportion of Hodgkin and Reed-Sternberg cells in about 40%
classical Hodgkin lymphoma cases (negative for CD20 and CD79a)
is in keeping with gene expression profile analysis of Hodgkin
lymphoma cell lines.47,48 In fact, the latter shows that, unlike other
B-cell–associated transcripts such as CD19, CD20, CD22, CD79a,
and IgM,47,48 TPD52 appears to be expressed in tumor cells of
Hodgkin lymphoma (Riccardo Dalla Favera, personal written
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communication, February 2003). These data have diagnostic
implications. Since TPD52 is not expressed in normal and neoplas-
tic peripheral T cells, it could be useful, in combination with
PAX549 for the differential diagnosis between tumor cell–rich
Hodgkin lymphoma and ALK-negative anaplastic large-cell lym-
phoma (2 neoplasms requiring different therapeutic approaches).
An example of such an application is depicted in Figure 6, and
studies are in progress in a larger number of cases.
Moreover, due to its lack of reactivity with normal hemato-
poietic cells, the B28p mAb can also be used in combination
with anti-CD13850 to quantify plasma cells in the bone marrow.
This is of value in the differential diagnosis between multiple
myeloma and monoclonal gammopathy of “undetermined”
significance (MGUS) and in the assessment of minimal residual
disease after conventional therapy or peripheral stem cell
transplantation.
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